Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ALTERATIONS IN THE SKIN MICROBIOTA ARE ASSOCIATED WITH SYMPTOM SEVERITY IN MYCOSIS FUNGOIDES

ABSTRACT: ALTERATIONS IN THE SKIN MICROBIOTA ARE ASSOCIATED WITH SYMPTOM SEVERITY IN MYCOSIS FUNGOIDES

PROVIDER: PRJNA772353 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16474800_1.fastq.gz	Fastqsanger.gz
	SRR16474800_2.fastq.gz	Fastqsanger.gz
	SRR16474801_1.fastq.gz	Fastqsanger.gz
	SRR16474801_2.fastq.gz	Fastqsanger.gz
	SRR16474802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 156

Similar Datasets

ALTERATIONS IN THE SKIN MICROBIOTA ARE ASSOCIATED WITH SYMPTOM SEVERITY IN MYCOSIS FUNGOIDES

Project description:We identified skin microbiota signatures related to different symptoms, i.e. pain, pruritus, in patients with Mycosis Fungoides.

2022-04-11 | GSE186083 | GEO

Mycosis fungoides

Project description:Mycosis fungoides

| PRJNA430861 | ENA

RNAseq of the skin of patients with Mycosis fungoides

Project description:We performed transcriptome analysis and multimodal data integration of the transcriptome and the microbiome of the skin of Mycosis fungoides Patients.

2023-12-01 | GSE221148 | GEO

The Skin Microbiome of Mycosis fungoides

Project description:The Skin Microbiome of Mycosis fungoides

| PRJNA913116 | ENA

Mycosis fungoides

Project description:Mycosis fungoides (MF) is the most common and best studied of cutaneous T-cell lymphoma (CTCL). Three clinical cutaneous stages have been described (patch, plaque and tumor) as the disease progress developing also the disease lymph node, peripheral blood or systemic involvement in late stages. Clinical and pathologic diagnosis of early MF stages (patch and plaque) is difficult as its morphologic similarity to inflammatory dermatoses and low proportion of tumoral cells.

2018-06-21 | GSE109421 | GEO

"Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides".

Project description:Cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma, is thought to arise from mature tissue-resident memory T cells. The most common subtypes include Mycosis Fungoides and Sezary Syndrome. The role of skin microbiota remains unclear in the symptom manifestation of MF. Among 39 patients with MF, we analyzed bacteria colonizing MF lesions and non-lesional skin in the contralateral side and characterized regional changes in the skin microbiota related to MF involvement using the difference in relative abundance of each genus between lesional and contralateral non-lesional skin. We investigated the relationship between these skin microbiota alterations and symptom severity. No statistically significant difference was found in bacterial diversity and richness between lesional and non-lesional skin. Different skin microbiota signatures were associated with different symptoms. More pronounced erythema in the lesions was associated with an increase in Staphylococcus. Pain and thick skin in the lesions were associated with a decrease in Propionibacterium. The results of this pilot study suggest that the skin microbiota plays an important role in changing skin phenotypes among patients with MF. Larger skin microbiota studies are needed to confirm these findings and support the use of antibiotic treatment to mitigate CTCL symptoms.

| S-EPMC9152451 | biostudies-literature

CD8+ T lymphocytes in hypopigmented mycosis fungoides: malignant cells or reactive clone?

Project description:We used targeted single cell RNA sequencing using a gene set composed of the BD Rhapsody Human Immune Response Panel, TCR panel, and a custom panel of 61 malignancy-associated genes and T/B cell receptor sequencing to characterize single cell populations in hypopigmented mycosis fungoides (HMF). Using a reference mapping model built on publically deposited classic mycosis fungoides single cell RNA sequencing datasets, we identified a predicted malignant cell population independent from the clonal T cell population in HMF.

2023-10-17 | GSE212146 | GEO

Genetic characterization of tumor-stage mycosis fungoides

Project description:Mycosis fungoides patients who develop tumors or extracutaneous involvement usually have a poor prognosis with no curative therapy available so far. In the present EORTC multicenter study, the genomic profile of 41 skin biopsies from tumor-stage mycosis fungoides was analyzed using a high-resolution oligo-array comparative genomic hybridization platform. Seventy-six percent of cases showed genomic aberrations. The most common imbalances were gains of 7q33.3q35 followed by 17q21.1, 8q24.21, 9q34qter and 10p14 and losses of 9p21.3 followed by 9q31.2, 17p13.1, 13q14.11, 6q21.3, 10p11.22, 16q23.2 and 16q24.3. Three specific chromosomal regions, 9p21.3, 8q24.21 and 10q26qter were defined as prognostic markers exhibiting a significant correlation with overall survival (P= .042, P= .017 and P= .022, respectively). Moreover, we have established two MFt genomic subgroups distinguishing a stable group (0-5 DNA aberrations) and an unstable group (> 5 DNA aberrations), showing that the genomic unstable group had a shorter overall survival (P=.05). We therefore conclude that specific chromosomal abnormalities, such as gains of 8q24.21 (MYC) and losses of 9p21.3 (CDKN2A, CDKN2B and MTAP), and 10q26qter (MGMT and EBF3) may play an important role in prognosis. In addition, we describe the MFt genomic instability profile. Forty-one MFt were studied by arrayCGH using the Human Genome CGH 44K microarrays (G4410B and G4426B, Agilent Technologies, Palo Alto, CA, USA). In each microarray experiment, DNA obtained from a 20x10 um sections snap frozen samples from tumoral MF lesions was compared with commercial pools of healthy female DNA (Promega, Madison, WI, USA).

2010-05-06 | E-GEOD-18098 | biostudies-arrayexpress

Genetic characterization of tumor-stage mycosis fungoides

2009-09-15 | GSE18098 | GEO

RNAseq of the skin of patients with Mycosis fungoides

Project description:RNAseq of the skin of patients with Mycosis fungoides

| PRJNA913117 | ENA